Fibroadenoma and the use of exogenous hormones: A case-control study

American Journal of Epidemiology

Volumn 127, Issue 3, 1988, Pages 454-461

  Canny, Priscilla F ^a   Berkowitz, Gertrud S ^b   Kelsey, Jennifer ^c   Livolsi, Virginia A ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast diseases; Breast neoplasms; Contraceptives, oral; Estrogens

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; CONTROLLED STUDY; DRUG THERAPY; FEMALE; FIBROADENOMA; HUMAN; HUMAN CELL; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PREVENTION; REVIEW;

ADENOFIBROMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CONNECTICUT; CONTRACEPTIVES, ORAL; EPIDEMIOLOGIC METHODS; ESTROGENS; FEMALE; HUMAN; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023854052     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a114822     Document Type: Article

References (32)

1. Azzopardi JG. Problems in breast pathology. London: WB Saundere, 1970.
2. Canny PF. The epidemiology of fibroadenoma. PhD. dissertation. New Haven, CT: Yale University School of Medicine, 1983.
3. Cole P, Elwood JM, Kaplan SD. Incidence rates and risk factors of benign breast neoplasms. Am J Epidemiol 1978;108:112-20.
4. Haagensen CD. Diseases of the breast. 2nd ed. Philadelphia: WB Saunders, 1971.
5. LiVolsi VA, Stadel BV, Kelsey JL, et al. Fibroadenoma in oral contraceptive users: a histopathologic evaluation of epithelial atypia. Cancer 1979;44:1778-81.
6. Vessey MP, Doll R, Sutton P. Oral contraceptives and breast neoplasia: a retrospective study. Br Med J 1972;3:719-24.
7. Sartwell PE, Arthes FG, Tonascia JA. Epidemiology of benign breast lesions: lack of association with oral contraceptive use. N Engl J Med 1973;288:551-4.
8. Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Lancet 1973;1:1399-1404.
9. Kelsey JL, Lindfore KK, White C. A case-control study of the epidemiology of benign breast diseases with reference to oral contraceptive use. Int J Epidemiol 1974;3:333-40.
10. Ravnihar B, Seigel DG, Lindtner J. An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Eur J Cancer 1979; 15:396-105.
11. Brinton LA, Vessey MP, Flavel R, et al. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-14.
12. Parazzini F, La Vecchia C, Franceschi S, et al. Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 1984;120:115-22.
13. Ory H, Cole P, MacMahon B, et al. Oral contraceptives and reduced risk of breast diseases. N Engl J Med 1976, 94:419-22.
14. Royal College of General Practitioners' Oral Contraception Study. Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet 1977;1:624.
15. Kelsey JL, Holford TR, White C, et al. Oral contraceptives and breast disease: an epidemiological study. Am J Epidemiol 1978; 107:236-44.
16. Trapido EJ, Brinton LA, Schairer C, et al. Estrogen replacement therapy and benign breast disease. JNCI 1984;73:1101-5.
17. Berkowitz GS, Kelsey JL, LiVolsi VA, et al. Oral contraceptive use and fibrocyatic breast disease among pre- and postmenopausal women. Am J Epidemiol 1984;120:87-96.
18. Hollingshead AB. Two factor index of social position. New Haven, CT: August B. Hollingshead Publications, 1957.
19. Hatcher RA, Stewart GK, Stewart FS, et aL Contraceptive technology. 12th ed. New York: Irvington Publishers Inc., 1984.
20. Geschickter CF, Lewis D. Pregnancy and lactation changes in fibroadenoma of the breast. Br Med J 1938; 1:499-504.
21. Goldenburg VE, Wiegenstein L, Mottet NK. Florid breast fibroadenomas in patients taking oral contraceptives. Am J Clin Pathol 1968;49:52-9.
22. Nomura A, Comstock GW, Tonascia JA. Epidemiologic characteristics of benign breast disease. Am J Epidemiol 1977;105:505-12.
23. Robbins SL. Pathology. 3rd ed. Philadelphia; WB Saunders, 1967.
24. Heiman J, Krehbiel OF. The influence of breast hormones on breast hyperplasia and tumor growths in rats. Am J Cancer 1936;27:450-73.
25. Mauvais-Jarvis P, Sitruk-Ware R, Kuttenn F, et al Luteal phase insufficiency: a common pathophysiologic factor in development of benign and malignant breast diseases. In: Taylor DJ, Bulbrook RD, eds. Commentaries in research on breast disease. Vol. 1. New York: Alan R. Loss, 1979:25-59.
26. Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P. Benign breast disease. I. Hormonal investigation. Obstet Gynecol 1979;53:457-60.
27. Huggins GR, Giuntoli RL. Oral contraceptives and neoplasia. Fertil Steril 1979;32:1-23.
28. FDA Drug Bull 1984;14:2-3.
29. Em8ter VL. The epidemiology of benign breast disease. Epidemiol Rev 1981;3:184-202.
30. National Center for Health Statistics. Contraceptive use, United States 1982.
31. Rockville, MD: National Center for Health Statistics, 1986. (Vital and Health Statistics, Series 23. Data from the National Health Survey, no. 12) (DHEW publication no. (DHS)86-1988).
32. Moskowitz M, Gartside P, Wirman JA, et al. Proliferative disorders of the breast as risk factors for breast cancer in a self-screened population: pathologic markers. Radiology 1980;134:289-91.